Myopericarditis in a previously healthy adolescent male following COVID-19 vaccination: A case report.
Acad Emerg Med
; 28(8): 918-921, 2021 08.
Article
in English
| MEDLINE | ID: covidwho-1270817
ABSTRACT
We report the case of a previously healthy 16-year-old male who developed myopericarditis following the second dose of his Pfizer-BioNTech COVID-19 vaccine, with no other identified triggers. Adolescents and young adults experiencing chest pain after COVD-19 vaccination should seek emergent medical care, and emergency providers should have a low threshold to consider and evaluate for myopericarditis. More data are needed to better understand the potential association between COVID-19 vaccines and myopericarditis. If a true causal link is identified, the risk must also be viewed in context with the millions of patients who have been safely vaccinated and the known morbidity and mortality from COVID-19 infection. As we see widespread vaccine rollout, it is important that all potential adverse reactions are reported as we continue to monitor for more rare but potentially serious side effects not identified in vaccination trials.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19
/
Myocarditis
Type of study:
Case report
/
Experimental Studies
/
Prognostic study
Topics:
Vaccines
Limits:
Adolescent
/
Adult
/
Humans
/
Male
/
Young adult
Language:
English
Journal:
Acad Emerg Med
Journal subject:
Emergency Medicine
Year:
2021
Document Type:
Article
Affiliation country:
Acem.14322
Similar
MEDLINE
...
LILACS
LIS